T-Cell and NK-Cell Neoplasm

Diseases /

Back to Diseases List

Overview

Clinical Trials

View Clinical Trials for T-Cell and NK-Cell Neoplasm

There are 3 clinical trials for T-cell and NK-cell neoplasm, of which 1 is open and 2 are completed or closed. Of the trials that contain T-cell and NK-cell neoplasm as an inclusion criterion, 2 are phase 1 (0 open) and 1 is phase 2 (1 open).

Anti-thymocyte globulin, crenigacestat, and cyclophosphamide are the most common interventions in T-cell and NK-cell neoplasm clinical trials.

Drugs Being Investigated in T-Cell And NK-Cell Neoplasm Trials by Recruiting Status

Significant Genes in T-Cell and NK-Cell Neoplasm

ABL1 +

ABL1 is an inclusion eligibility criterion in 1 clinical trial for T-cell and NK-cell neoplasm, of which 1 is open and 0 are closed. Of the trial that contains ABL1 status and T-cell and NK-cell neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].

AFF1 +

AFF1 is an inclusion eligibility criterion in 1 clinical trial for T-cell and NK-cell neoplasm, of which 1 is open and 0 are closed. Of the trial that contains AFF1 status and T-cell and NK-cell neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].

BCR +

BCR is an inclusion eligibility criterion in 1 clinical trial for T-cell and NK-cell neoplasm, of which 1 is open and 0 are closed. Of the trial that contains BCR status and T-cell and NK-cell neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].

FLT3 +

FLT3 is an inclusion eligibility criterion in 1 clinical trial for T-cell and NK-cell neoplasm, of which 1 is open and 0 are closed. Of the trial that contains FLT3 status and T-cell and NK-cell neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].

IKZF1 +

IKZF1 is an inclusion eligibility criterion in 1 clinical trial for T-cell and NK-cell neoplasm, of which 1 is open and 0 are closed. Of the trial that contains IKZF1 status and T-cell and NK-cell neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].

KIT +

KIT is an inclusion eligibility criterion in 1 clinical trial for T-cell and NK-cell neoplasm, of which 1 is open and 0 are closed. Of the trial that contains KIT status and T-cell and NK-cell neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].

KMT2A +

KMT2A is an inclusion eligibility criterion in 1 clinical trial for T-cell and NK-cell neoplasm, of which 1 is open and 0 are closed. Of the trial that contains KMT2A status and T-cell and NK-cell neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].

MECOM +

MECOM is an inclusion eligibility criterion in 1 clinical trial for T-cell and NK-cell neoplasm, of which 1 is open and 0 are closed. Of the trial that contains MECOM status and T-cell and NK-cell neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].

MLF1 +

MLF1 is an inclusion eligibility criterion in 1 clinical trial for T-cell and NK-cell neoplasm, of which 1 is open and 0 are closed. Of the trial that contains MLF1 status and T-cell and NK-cell neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].

NPM1 +

NPM1 is an inclusion eligibility criterion in 1 clinical trial for T-cell and NK-cell neoplasm, of which 1 is open and 0 are closed. Of the trial that contains NPM1 status and T-cell and NK-cell neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].

PBX1 +

PBX1 is an inclusion eligibility criterion in 1 clinical trial for T-cell and NK-cell neoplasm, of which 1 is open and 0 are closed. Of the trial that contains PBX1 status and T-cell and NK-cell neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].

RPN1 +

RPN1 is an inclusion eligibility criterion in 1 clinical trial for T-cell and NK-cell neoplasm, of which 1 is open and 0 are closed. Of the trial that contains RPN1 status and T-cell and NK-cell neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].

TCF3 +

TCF3 is an inclusion eligibility criterion in 1 clinical trial for T-cell and NK-cell neoplasm, of which 1 is open and 0 are closed. Of the trial that contains TCF3 status and T-cell and NK-cell neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].

Disease Details

Parent(s)

Lymphocytic Neoplasm

Children

Mature T-Cell and NK-Cell Neoplasm and T-Cell Lymphoblastic Leukemia/Lymphoma

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/ [2018-08-28]. [2018-09-21].

2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.

3. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.